APC in IHP (on FDA FAERS)
Inside Health Policy covered our letter to FDA protesting the agency's recent (ridiculous) statement about adverse events and compounded GLP-1s:
APA’s (sic) letter objects to the use of FAERS data, saying the information is unverified and alleges the agency’s statement is “both inflammatory and misrepresentative.” The group says FDA fails to acknowledge in its statement the unreliability of FAERS reports or to differentiate between illicit, sometimes fraudulent substances acquired from unlicensed online pharmacies and compounded drugs prepared by legitimate state-licensed pharmacies.